or switching to exenatide once-weekly from sitagliptin, wasassociated with favourable 52-week changes in the urinaryalbumin ⁄creatinine ratio, B-type nat riuretic peptide and high- sensitivity C-reactive protei n. Patients who switched from pioglitazone exhibited a signiﬁcant decrease in B-typenatriuretic peptide, and increases in high-sensitivity C-reactive protein and plasminogen activator inhibitor-1, such that theseDIABETIC Medicine DURATION-2: switching from sitagliptin or pioglitazone to exenatide once-weekly •C. Wysham et al. ª2011 Amylin Pharmaceuticals, Inc. 712 Diabetic Medicine ª2011 Diabetes UK